🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. A clinical study to learn about the safety and effects of KIN-2787, a new oral anticancer drug for the treatment of patients with BRAF and/or NRAS Mutation-positive Solid Tumors

    Pierre Fabre Medicament

    Participants with BRAF and/or NRAS mutation positive tumors

    phase 1 other active

    1 trial

  2. A clinical study to test MEN2501 in patients with treatment-resistant ovarian cancer

    Stemline Therapeutics B.V.

    ​​Platinum-Resistant ovarian cancer​

    phase 1 other active

    1 trial

  3. A clinical study to test the safety (any good or bad effects) of CC-90011 in combination with standard of care (cisplatin and etoposide), on how long the drug can stay in the body and if it can control the disease of people diagnosed with extensive small cell lung cancer and have not had any previous treatment for the disease. CC-90011, single agent, will be also given in consolidation after completion of the 4 to 6 cycles of chemotherapy

    Celgene Europe Limited

    extensive stage small cell lung cancer

    phase 1 other active

    1 trial

  4. A clinical trial to learn about the effects of DAK539 on the blood levels of repaglinide, midazolam, drospirenone, and ethinyl estradiol in people with advanced cancer

    Novartis Pharmaceuticals

    Patients with advanced malignancies

    phase 1 other active

    1 trial

  5. A clinical trial to learn how liver function affects the blood levels of DAK539 in people with advanced cancer

    Novartis Pharmaceuticals

    Advanced Malignancies and Hepatic Impairment

    phase 1 other active

    1 trial

  6. A first-in-human study to learn about the safety of BAY 3547926 and how well it works in participants with advanced liver cancer

    Bayer AG

    hepatocellular carcinoma (HCC)

    phase 1 other active

    1 trial

  7. A first-in-human study to learn how safe the study treatment BAY2862789 is, to find the best dose, how it affects the body, what maximum amount can be given, how it moves into, through and out of the body, and how it acts on different tumors in participants with advanced solid tumors

    Bayer AG

    Advanced solid tumors, Non-small cell lung cancer

    phase 1 other active

    1 trial

  8. A phase 1 study of FluBHPVE6E7 immunotherapy in patients with HPV16-associated oropharyngeal squamous cell carcinoma

    Blue Earth Diagnostics Ireland Ltd

    Treatment of human papilloma virus (HPV) associated infections and cancers

    phase 1 other active

    1 trial

  9. A phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-DFC413 and safety and imaging properties of [68Ga]Ga-NNS309 in patients with solid tumors

    Novartis Pharmaceuticals

    Locally advanced unresectable or metastatic colorectal cancer (CRC), Locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC), Locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC), Locally advanced unresectable or metastatic soft tissue sarcoma (excluding GIST and Kaposi sarcoma), Locally advanced unresectable or metastatic HR+/HER2- ductal or lobular breast cancer (BC), Locally advanced unresectable or metastatic triple negative breast cancer (TNBC)

    phase 1 other active

    1 trial

  10. A phase I study of [177Lu]Lu-EVS459 in patients with ovarian and lung cancers

    Novartis Pharmaceuticals

    Advanced high-grade serous ovarian cancer (OC), Locally advanced unresectable or metastatic non-squamous non-small cell lung carcinoma (NSCLC)

    phase 1 other active

    1 trial

  11. A phase I study of [68Ga]Ga-DWJ155 in patients with advanced breast and NSCLC cancers

    Novartis Pharmaceuticals

    Advanced breast cancer and advanced NSCLC

    phase 1 other active

    1 trial

  12. A phase I, open-label, multi-center study of KFA115 as a single agent and in combination with pembrolizumab in patients with select advanced cancers

    Novartis Pharmaceuticals

    Thymic Carcinoma, Nasopharyngeal Cancer, Anal Cancer, Head and Neck Squamous Cell Carcinoma, Epithelial Ovarian Cancer, Cutaneous melanoma, Mesothelioma, Non-small cell lung cancer, Esophagogastric Cancer, Triple negative breast cancer, Microsatellite Instability High Colorectal Cancer, Clear Cell Renal Cell Carcinoma

    phase 1 other active

    1 trial

  13. A study in patients with different types of advanced cancer (solid tumors) to test different doses of BI 907828 (brigimadlin) in combination with BI 754091 (ezabenlimab) and BI 754111 or BI 907828 (brigimadlin) in combination with BI 754091 (ezabenlimab)

    Boehringer Ingelheim

    advanced solid tumors

    phase 1 other active

    1 trial

  14. A study in people with advanced cancer (solid tumours) to test different doses of BI 3810944 and to find out whether it helps

    Boehringer Ingelheim

    Melanoma, Solid tumours

    phase 1 other active

    1 trial

  15. A study in people with advanced cancer to test how well different doses of BI 3819026 are tolerated when taken alone and together with ezabenlimab

    Boehringer Ingelheim

    unresectable advanced or metastatic solid cancer

    phase 1 other active

    1 trial

  16. A study in people with advanced cancer to test whether the amount of BI 907828 in the blood is influenced by taking an OATP inhibitor or a CYP3 inhibitor

    Boehringer Ingelheim

    Solid cancer tumors

    phase 1 other active

    1 trial

  17. A study of ASP2138 given by itself or given with other cancer treatments in adults with stomach cancer, gastroesophageal junction cancer, or pancreatic cancer

    Astellas Pharma GmbH

    Gastroesophageal Junction (GEJ) Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma

    phase 1 other active

    1 trial

  18. A study of LOXO-783 in Patients with PIK3CA H1047R-Mutant Advanced Breast Cancer and Other Solid Tumors.

    Eli Lilly Co.

    Advanced Breast Cancer and Other Solid Tumors

    phase 1 other active

    1 trial

  19. A study of different dose levels of FluBHPVE6E7 or placebo in women infected with the virus Human Papilloma Type 16 (HPV 16).

    Blue Earth Diagnostics Ireland Ltd

    Treatment of human papilloma virus (HPV) associated infections, precancers and cancers

    phase 1 other active

    1 trial

  20. A study of gilteritinib in adults with advanced ALK-positive non-small cell lung cancer (NSCLC)

    Astellas Pharma GmbH

    Locally advanced or metastatic NSCLC

    phase 1 other active

    1 trial

  21. A study of safety and efficacy of novel targeted therapy combinations in adult patients with advanced or metastatic colorectal cancer.

    Novartis Pharmaceuticals

    Advanced or metastatic BRAF V600 colorectal cancer.

    phase 1 other active

    1 trial

  22. A study of the PAN-KRAS inhibitor LY4066434 in participants with KRAS mutant solid tumors.

    Eli Lilly Co.

    Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor Metastatic Solid Tumor, PanKRAS.

    phase 1 other active

    1 trial

  23. A study of the safety, tolerability, biological effect, and efficacy of allogenic natural killer cells in combination with trastuzumab and pertuzumab in adult patients with refractory metastatic Her2 positive breast cancer

    The George Institute

    Refractory metastatic Her2 positive breast cancer

    phase 1 other active

    1 trial

  24. A study to Evaluate AB308 in Combination with AB122 in Participants with Advanced Malignancies (ARC-12)

    Arcus Biosciences

    Multiple Myeloma, Diffuse large B cell lymphoma (DLBCL), Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Melanoma, Advanced Solid Tumor, Gastrointestinal (GI) cancer, Hematological (heme) cancer, Gynecological (Gyn) cancer, Non-small cell lung cancer (NSCLC), Non-Hodgkin Lymphoma, Gastric Cancer, Cervical Cancer

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources